A study to determine the pharmacokinetics of cediranib in Chinese patients with advanced solid malignancies

Study identifier:D8480C00060

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, randomised, multi-centre, open-label study to determine the pharmacokinetics and tolerability of cediranib (RECENTIN™, AZD2171) following a single and multiple oral 20mg or 30 mg doses in Chinese patients with advanced solid malignancies

Medical condition

Advanced solid malignancies

Phase

Phase 1

Healthy volunteers

No

Study drug

cediranib (RECENTIN TM, AZD2171)

Sex

All

Actual Enrollment

20

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Sept 2009
Primary Completion Date: 01 May 2010
Study Completion Date: 01 Apr 2011

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria